Editorial Quantitative EEG and Substance
As I write this editorial introducing a supplement to the October issue dealing with quantitative EEG (OEEG) changes associated with substance abuse, I am looking at a small strip of paper recently given to me by Dr. Charles Henry. It is a portion of a single-channel EEG recorded on ticker tape in 1939, and we are considering how and where to display and preserve it, perhaps on the Offner instrument first used by Dr. Milton Parker to record EEGs at Ohio State in 1946, now stripped of its galvanometers but handsomely stained and polished. These artifacts and others like them no doubt in the possession of many readers remind us of a time when electroencephalography promised to reveal many exciting secrets of normal and abnormal brain function. First in the hands of Hans Berger and then in the laboratories of Frederic and Erna Gibbs as well as the other EEG pioneers, alterations in the morphology, frequency, and eventually topography of EEG signals promised better understanding and more accurate diagnosis of neurological and psychiatric disorders, and seemed to offer a way to measure the effect of drugs on the brain. Some of that excitement has diminished over the past half century, as the diagnostic palm has passed to some degree from EEG to imaging modalities, first computed tomography and then magnetic resonance, and now SPECT and PET and functional MRI. The principal remaining advantages for EEG and related tests are relative ease and cheapness of administration, and welldoc u m e n te d sensitivity, part i c u I a r I y in patients with epilepsy, to functional alterations that have no counterpart in altered brain structure. One might think that fairly inexpensive tests that could be quickly conducted and readily repeated would find great favor at a time of financial constraint and cost containment in medicine. Moreover, theoretical tools for processing and transformation of the EEG signals in various ways have been available for some time, and the computer revolution that has so comprehensively transformed modern medicine might be expected to facilitate the extraction from complex brainwaves of patterns and changes that are not as rapidly or easily grasped by the unaided eye. It is a great irony indeed that, as the Decade of the Brain draws to its close, the role of the fastest and cheapest rneasure of brain function in an outpatient setting is a matter of doubt, and as the Century of the Computer reaches its end, the application of computer techniques to electrodiagnosis is a matter of controversy.
The regular reader of Clinical EEG will know that issues of sensitivity and specificity in EEG and evoked potentials are'regularly dealt with. The potential perils of QEEG techniques, particularly in psychiatric and neurodevelopmental applications, have also been discussed in these pages. It is nevertheless exciting to see neurophysiology generally and QEEG particularly advance to a point from which it may have some influence on defining and solving the problems of the day. Dr. Braverman's work with Dr. Blum gives new meaning to the concept of cerebral dysrhythmia as a medical disorder of the brain which is exacerbated by drug abuse.
There is probably no reader, in the United States or elsewhere, who is not aware of the medical, economic, social and political aspects of escalating use of illicit substances, particularly among young people. It is generally agreed that neurologic examination, CAT scan, and MRI imaging are of limited value in measuring the effects of substance use and abuse, short of long-term systemic consequences or catastrophic complications. Despite much work in this area, standard EEG and evoked potentials are also of limited value. There is increasing evidence, much of it in this journal, that QEEG techniques improve neuropsychiatric diagnosis and facilitate psychotropic drug treatment. Drs. Eric Braverman and Kenneth Blum have, in extensive studies retrospective and prospective over a seven-year period, shown QEEG changes not evident in other clinical and imaging modalities in patients with substance abuse problems not yet attended by long-term complications, in whose care education and rehabilitation are still possible and crucially important. Such findings suggest that QEEG may be a cost-effective adjunct in the evaluation, treatment, and education of substance-abusing patients. As the problems of drug abuse and its consequences are the focus of increasing concern in our society, this may be an area in which clinical neurophysiology can beneficially impact a major public health problem, as Berger, the Gibbses, and so many others attempted to do.
This prospect should be exciting to electroencephalographers. Because of this excitement and the timeliness of the subject, we published the Braverman and Blum study in an expedited fashion, as a supplement so that color graphics would be readily visible to all. We hope that this In the last five years there has been a surge in substance abuse amongst teenagers in the United States. Unfortunately this increase parallels expanding scientific knowledge about the damaging effects of drugs on brain function. The Braverman and Blum study identifies increased electrophysiological disturbances in substance abuse disorder subjects. They correlate such dis-timely contribution will draw attention to our discipline and journal, and to the promise of pharmaco electroencephalography for modern neuropsychiatry. Finally, we are grateful to Dr. David Smith, President of the American Society of Addiction Medicine, for putting this work in the perspective of current addiction research and treatment. This supplement may be the beginning of fruitful collaboration between clinical neurophysiology and clinical addictionology.
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Chief Editor Clinical Electroencephalography turbances with genetic evidence suggesting a premorbid existence of brain dysfunction making the subjects more susceptible to the disabling effects of drug abuse. Such research has important implications for better understanding of the biological basis for the disease of addiction as well as providing a stronger scientific basis for prevention and early intervention for high risk individuals.
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